3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
9
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Hemorrhage
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cyst
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neurotoxicity Syndromes
1
Myofibroma
1
Multiple Myeloma
1
Metabolic Diseases
1
Melanoma
1
Interventions
Rituximab
49
Cyclophosphamide
28
venetoclax
24
Bendamustine Hydrochloride
24
obinutuzumab
22
ibrutinib
21
Chlorambucil
20
fludarabine
16
fludarabine phosphate
15
idelalisib
13
acalabrutinib
11
pirtobrutinib
7
ofatumumab
7
zanubrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cyclosporine
5
Radiotherapy
4
Prednisone
4
Doxorubicin
4
duvelisib
3
Whole-Body Irradiation
3
Specimen Handling
3
Methotrexate
3
Lenalidomide
3
Filgrastim
3
Epoetin Alfa
3
Cyclosporins
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Saline Solution
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled